Print

Active Biotech AB Interim report January - June 2015

2015-08-07

·Operations focused on the laquinimod projects and organization adjusted accordingly

Laquinimod
·The pivotal CONCERTO clinical Phase III study in relapsing remitting MS (RRMS) is fully enrolled and results are expected in 2017
·The first patient was enrolled for the ARPEGGIO Phase II study, which will evaluate laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
·The Phase II study LEGATO-HD into Huntington's disease is proceeding according to plan
·Laquinimod presented by Teva at the AAN Annual Meeting on April 18-25, 2015

Tasquinimod
·Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod significantly reduced the risk of radiographic cancer progression compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28).
·Further development of tasquinimod discontinued and the collaboration agreement with Ipsen terminated

ISI
·Only commercial activities will be conducted from 2016

Financial summary

MSEK April - June Jan. - June Jan. - Dec.
2015 2014 2015 2014 2014
Net sales 3.2 2.7 6.1 4.9 10.4
Operating loss -70.1 -57.9 -127.5 -117.2 -228.5
Loss for the period -71.4 -57.7 -129.3 -117.9 -231.5
Loss per share (SEK) -0.79 -0.77 -1.44 -1.57 -3.02
Cash and cash equivalents 186.6 227.7 328.5


For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

The report is also available at www.activebiotech.com

Active Biotech AB
Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00


pdfActive Biotech AB Interim report January - June 2015



Back